• 2021

    XNW3009(hURAT1): Ph II

    XNW4107(BLI):QIDPand FTD approval and Ph III in 2021

    XNW1011(BTK):oncologyindications expected to enter Ph Ib/II 2021

    Construction 5 acres of manufacturingsite in Suzhou Industrial Park

    IPO Application

  • 2020

    XNW4107(BLI)entered clinical trials in US


    3 Projects entered IND-Enabling

    Official Opening of Suzhou SangtiandaoR&D Building

    Unicorn Cultivation Enterprise and Gusu Innovation and EntrepreneurLeadership Talents Plan

    1+Billion RMBFinancing(C&D Round)

  • 2019

    XNW1011(BTK) INDApproval in Australia and China

    XNW3009(hURAT1)PhI in Australia and IND approved in China

    XNW7201(Wnt)IND Approved inAustralia and China

    Application combinedwith SinoMab in autoimmune indications

    Dual Entrepreneurship Plan of Jiangsu

    Suzhou high growth innovative cultivation enterprise

    B+Round Financing

  • 2018

    3 Projects started IND


    Selected as Suzhou Industrial Park Unicorn Cultivation Enterprise once again

    Collect ALL the awards among enterprises signed by Suzhou Free Trade Zone

    B Round Financing

  • 2017


    Suzhou lab in operation

    Unicorn Cultivation Enterprise in Suzhou Industrial Park 

    Awarded Science and Technology Leading Talents of Suzhou Industrial Park

    A Round Financing

Address · 218 Sangtian Street, Building 22, Suzhou Industrial Park, Jiangsu, P.R. China,215000
Tel · +0512-89162086
Mailbox · info@sinovent.com
Follow us